The Corporate Council is a membership program that allows the Society’s leadership to engage and share insights with representatives of companies developing biologics, pharmaceuticals, medical devices and diagnostics prescribed by clinical neurologists.
The Corporate Council serves in an advisory role to the Society’s leadership by offering the industry perspective on issues impacting clinical care, patient access and the field of neurology.
CNSA thanks and acknowledges the companies involved in the Corporate Council:
- Acadia Pharmaceuticals
- Avanir Pharmaceuticals
- Eli Lilly & Company
- Greenwich Biosciences
- Ionis Pharmaceuticals, Inc
- Neurocrine Biosciences
To learn more about joining the Corporate Council, contact:
Acting Executive Director, CNSA